DOI record:
{
"DOI": "10.21109/kesmas.v16i4.5433",
"ISSN": [
"2460-0601",
"1907-7505"
],
"URL": "http://dx.doi.org/10.21109/kesmas.v16i4.5433",
"abstract": "<jats:p>COVID-19 is a major public health problem, with still questionable specific cure. Favipiravir is a COVID-19 antiviral that is potentially a therapy for COVID-19. This study aimed to analyze its effectivity and safety in moderate to critical hospitalized patients. This study was a retrospective cohort in a tertiary referral hospital in Denpasar City, Bali Province, Indonesia, from August 2020 to January 2021. There was a total of 192 patients; 96 in the favipiravir group and 96in the non-favipiravir group (remdesivir/oseltamivir). Effectivity was measured by assessing the clinical condition at the end of the isolation period of 14 days. The favipiravir group showed better clinical conditions than the non-favipiravir group (79.2% vs. 56.3%; adjusted RR = 2.196; 95% CI = 1.084 – 4.451; p-value= 0.029), seen from being free of fever and respiratory problems. Stratification analysis demonstrated that the clinical improvement was significantly differentin the severe/critical group in favor of favipiravir (RR = 1.573; 95% CI = 1.139-2.172). The most common non-serious adverse events (AE) found in the use offavipiravir were gastrointestinal disturbances (12.5%). In brief, favipiravir is effective in severe/critical cases, and less serious AE were found in its use. Appropriate treatment is expected to help in reducing the public health burden.</jats:p>",
"author": [
{
"ORCID": "http://orcid.org/0000-0002-2437-5072",
"affiliation": [],
"authenticated-orcid": false,
"family": "Damayanti",
"given": "Herni",
"sequence": "first"
},
{
"affiliation": [],
"family": "Sajinadiyasa",
"given": "I Gede K",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Risni",
"given": "Hindun Wilda",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Sauriasari",
"given": "Rani",
"sequence": "additional"
}
],
"container-title": "Kesmas: National Public Health Journal",
"container-title-short": "Kesmas: National Public Health Journal",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
11,
3
]
],
"date-time": "2021-11-03T01:05:07Z",
"timestamp": 1635901507000
},
"deposited": {
"date-parts": [
[
2021,
12,
6
]
],
"date-time": "2021-12-06T13:17:05Z",
"timestamp": 1638796625000
},
"indexed": {
"date-parts": [
[
2022,
3,
30
]
],
"date-time": "2022-03-30T12:47:26Z",
"timestamp": 1648644446076
},
"is-referenced-by-count": 0,
"issue": "4",
"issued": {
"date-parts": [
[
2021,
11,
1
]
]
},
"journal-issue": {
"issue": "4",
"published-online": {
"date-parts": [
[
2021,
11,
1
]
]
}
},
"license": [
{
"URL": "http://creativecommons.org/licenses/by-sa/4.0",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
11,
1
]
],
"date-time": "2021-11-01T00:00:00Z",
"timestamp": 1635724800000
}
}
],
"link": [
{
"URL": "https://journal.fkm.ui.ac.id/kesmas/article/viewFile/5433/1245",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://journal.fkm.ui.ac.id/kesmas/article/viewFile/5433/1245",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "8818",
"original-title": [],
"prefix": "10.21109",
"published": {
"date-parts": [
[
2021,
11,
1
]
]
},
"published-online": {
"date-parts": [
[
2021,
11,
1
]
]
},
"publisher": "Kesmas: Jurnal Kesehatan Masyarakat Nasional",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://journal.fkm.ui.ac.id/kesmas/article/view/5433"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Public Health, Environmental and Occupational Health",
"Health Policy",
"Epidemiology"
],
"subtitle": [],
"title": "The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia",
"type": "journal-article",
"volume": "16"
}
